Curriculum Vitae of Giovina Ruberti

Personal data

Place	Rome (Italy)
Date of birth	29-04-1960
Nationality	Italian

Education

1979	High School Diploma, Liceo Scientifico J.F. Kennedy, Rome (60/60)
1985	Medical Degree University of Rome La Sapienza (cum laude). Tutor Prof. Vincenzo Barnaba

Current Position

2002-present	Research Director at the National Research Council (CNR), Institute of Cell Biology (IBC-CNR, 2002-2010) and Institute of Cell Biology and Neurobiology (IBCN-CNR, 2010-present)

Professional Employment History

2002-present	Research Director first at IBC-CNR (2002-2010) and then at IBCN-CNR (2010-present
25/11- 21/12/2010	Acting Director of the IBC-CNR
2001-2002	Senior researcher at the IBC-CNR
1996-2001	Researcher at the IBC-CNR
1992-1996	Research Contract (ex art. 36 law 70/75) at the IBC-CNR
29/12-31/12/89	Research Contract (ex art. 36 law 70/75) at the Institute of Experimental Medicine-CNR
1987-1991	Postdoctoral Fellow at the Department of Medicine, Division of Immunology Stanford University (Laboratory Prof. Garrison Fathman)
1987	Award “Istituto Pasteur-Fondazione Cenci Bolognetti” University of Rome La Sapienza Foundation, for a two years post-doctal fellowship abroad
02/1987	Visiting Fellow at the German Cancer Research Center (DKFZ) Heidelberg (Laboratory Dr. CM Weyand and Dr. J Goronzy)
1985-1987	Visiting Fellow at the Department of Medicine, Division of Immunology University of Rome La Sapienza (Laboratory Prof. Vincenzo Barnaba)
1984-1985	Visiting Fellow at the Department of Medicine, Division of Virology University of Rome La Sapienza (Laboratory Dr. Stefano Vella and Prof. Giovanni Rocchi)

Appointments

2008-2017	Italian Representative (MIUR) for the European Joint Undertaking-Innovative Medicines Initiative (JU IMI) (http://www.imi.europa.eu/), As member of the IMI-SRG in these years I have been involved in the elaboration and implementation of the IMI SRA, in the preparation of IMI calls, in the communications of IMI-JU with national institutions and public and private research groups.
2009-2017	Italian delegate (MIUR) in the Management Board of the Joint Programming Initiative "A Healthy diet for a healthy life" (JPI-HDHL) (www.healthydietforhealthylife.eu) and elected member of the Steering Committee. I participated to the analysis of the options, assessment of expected impacts and selection of instruments for SRA implementation; organization of Task Forces and preparation of joint initiatives call documents; organization of workshops, meetings and telematic conferences to stimulate and support the participation of national scientific groups to the JPI HDHL Projects.
9/2009-6/2012	Collaborator of the DGIR-MIUR for improving the italian competitiveness in european and non-european R&D Programmes and actions
2007-2012	Collaborator of the CNR, Department of Life Sciences (DSV). My activity aimed mainly to stimulate and facilitate collaborations of the CNR scientific community with public and private national research organizations, to promote and facilitate networking and participation of CNR scientists to regional, national and international scientific programs and projects
2010-2012	Head of the CNR-DSV Project "Molecular mechanisms and signals regulating cell proliferation, cell differentiation and cell death"
3/2010-2015	Head of the IBCN-CNR Research group (Commessa) "Signal transduction and multifactorial diseases"
2014-present	Alternate Delegate (MIUR) in the SC1 Programme Committee (PC) Horizon 2020 for the "Health, demographic change and well-being" configuration. Participation to PC and national meetings and elaboration of documents.
2014-present	National expert (MIUR) for the SC2 Horizon 2020 "'Food security, sustainable agriculture and forestry, marine and maritime and inland water research and the bioeconomy'. Participation to national meetings and elaboration of documents.

Committees

2007-2010	Member of the working group (GdL): Technology Transfer, CNR-DSV
2008-2011	Member of the GdL FRIEnd, Female Researchers in Europe Window
2010-2011	Member of the GdL Polo BioNeuro coordinated by the CNR-DSV to elaborate a working document for the development of a centre of excellence in biology and neuroscience in the North Area of Rome
1995-present	Member of CNR-Committees for the selection of post-doctoral fellows and researchers at the IBC (1995-2010) and at the IBCN (2010-present)

2010-2011	Member of CNR-Committees for the evaluation of candidates to CNR staff positions in CNR-Institutes of the DSV

Scientific activity

Trained in immunology, cellular biology and molecular biology at the University of Rome La Sapienza (1984-1987) and at the Stanford University's School of Medicine (1987-1991), I acquired considerable expertise and experience in the study of complex biological processes including cell growth and cell fate of hematopoietic cells, signal transduction pathways mediated by immune cell surface receptors such as T cell receptor and Major histocompatibility antigens, mouse genetics and analysis of immunological phenotypes in healthy and autoimmune disease models. In 1992, I established a Signal Transduction laboratory at the IBC-CNR (now IBCN-CNR), committed to the discovery of mechanisms controlling programmed cell death in physiology, cancer and autoimmune diseases. More recently, I coordinated two large multidisciplinary projects, one focused on cancer biology, supported by the Ministry of Economics and Finances (CNR Project "Innovative drugs and biotechnology networks of Quality" (FaReBio di Qualità) and involving research groups of the CNR-IBCN, -IBBE (Institute of Biomembranes and Bioenergentics, Bari), -IBIM (Institute of Biomedicine and Molecular Immunology, Palermo) and the second focused on Schistosomiasis, supported by MIUR (Project CNR-CNCCS) and involving research groups of the CNR-IBCN and IRBM Science Park. Both projects aim to: i) develop cellular and murine models and functional studies for the discovery of innovative lead targets/compounds potentially relevant for unmet medical needs; ii) integrate skills, qualities, strengths, expertise and competencies of the CNR; iii) facilitate collaboration with small and medium enterprises and improve regional innovation in the field of drugs and diagnostic tools discovery.

In summary, the scientific activity has been mainly directed to the following thematic areas:

• Structure/function relationship between TCR and antigen recognition in physiology and autoimmune diseases

• Proteins of the Death Domain Fold family (i.e. Fas Receptor, FADD, TRADD and Caspases): apoptotic and non apoptotic functions (i.e. cell cycle, cell adhesion and cell migration);

• Innovative Drugs: Cellular, parasites and murine models and functional studies (Molecular mechanisms of drug resistance in lung cancer model systems; Lead targets/compounds identification for Schistosomiasis)

Scientific coordination of national and international Research Projects

1993-1995	VI-VII-VIII AIDS Research Project (National Institute of Health, ISS)"Polymorphisms and expression analysis of the pro-apoptotic Fas gene in healthy and HIV positive individuals"
1995-1997	AIRC (Italian Association for Cancer Research) "Regulation of Fas-mediated apoptosis"
1996	IX AIDS Project (ISS) "Role of Fas in T lynphocyte depletion in HIV infection: Fas variants and identification of genes involved in apoptotic signal trasnsduction pathways"
1996-1998	Telethon "Role of Fas and Fas Ligand in the pathogenesis of type I diabetes".
1997-1998	AIDS (ISS) "Regulation of Fas-mediated apoptosis. Strategies to interfere with increased susceptibility to apoptosis in HIV infection"
1998-2000	AIRC "Identification and characterization of mechanisms that regulate the CD95 induced apoptotic signal"

2001	AIRC "Trafficking and compartmentalization analysis of apoptotic elements regulating Fas and FADD signaling"
2002	Juvenile Diabetes Research Foundation, Innovative USA Grant "Role of T1DMassociated CTLA-4 Polymorphisms on protein Trafficking and Compartmentalization"
2005	CNR-curiosity driven Project (*Ricerca a tema libero*) "FADD and TRADD non apoptotic functions"

Coordinator of a research unit within Networking Research Projects

1994-1997	Human Capital and Mobility European Commission "Signal transduction mechanisms that control the activation, growth and apoptosis of T lymphocytes"
1996-1997	CNR Strategic Project "Cell cycle and apoptosis" – IBC-CNR unit: "Modulation of Fas and FasL in physiologic and patological conditions"
1997-1999	Biomed 2 EC "Surface receptor-induced apoptosis in transformed cells: defining the molecular events involved in TNF-R1 and Fas apoptotic signaling"
1998-2000	CNR *Progetto Finalizzato Biotecnlogie* "Regulation of Fas-mediated apoptosis. Strategies to interfere with apoptotic signaling"
1998-2000	Training and Mobibility European Commission "Regulation of apoptosis in tissue homeostasis and cancer: role of TNF-R1 and Fas"
2000-2001	CNR Strategic Project "Post-genomics technologies" - IBC-CNR unit: "Identification of novel genes that modulate the apoptotic process"
2002-2003	MIUR-CNR Project Functional genomics–Function of genes at the cellular and organism level. The IBC-CNR unit coordinated also research groups of the University of Rome Tor Vergata and of the University of Udine "**CO**ntrolling **M**odulated **E**lements **T**ransducing **A**poptosis (COMETA)"
2005-2007	Juvenile Diabetes Research Foundation-Telethon. "IDDM12 Locus Analysis in T1DM: Identification and Characterization of Functional Polymorphisms"
2012-2013	MIUR-PRIN2009 "Resistance to target therapy and ErbB receptors inhibitors"
2011-2013	Project "Innovative drugs and biotechnology networks of Quality" (FaReBio di Qualità) supported by a grant from the Italian Ministry of Economics and Finances to the CNR. IBCN-CNR Unit: "Laboratory node for Innovative drug discovery: cellular and murine models and functional studies. The IBCN-CNR unit coordinates also research groups of IBBE-CNR and IBIM-CNR.
2012-2017	Project CNR-CNCCS "Collezione di composti chimici ed attività di screening" Public-private project in collaboration with IRBM Science Park srl.
2012-2017	Project CNR-CNCCS Schistodiscovery– "Schistosomiasis - Innovative drugs discovery", in collaboration with IRBM Science Park
2013-2016	Progetto premiale "Medicina personalizzata" BBT (Biomarcatori, Bersagli, Tumori) - Identificazione di biomarcatori e bersagli in tumori umani

	polmonari farmaco-resistenti ed in tumori neuroendocrini per approcci diagnostici e terapeutici innovativi.
2014-2015	CNR-Regione Lazio Sviluppo di piattaforme scientifiche e tecnologiche e di librerie molecolari ad alto contenuto innovativo applicate a malattie rare e trascurate. SP3 Approcci di ricerca traslazionale per Malattie Rare e Trascurate. WP4 Sviluppo piattaforme di drug discovery per target epigenetici Public-private project in collaboration with IRBM Science Park srl."Schistosomiasis: identification of epigenetic targets"
2016-2018	PRIN 2015 20154JRJPP "Towards multi-stage drugs to fight poverty related and neglected parasitic diseases: synthetic and natural compounds directed against Leishmania, Plasmodium and Schistosoma life stages and assessment of their mechanisms of action".

Reviewer Activity

Scientific Journals
BBA Molecular Cell Research, Cell Death and Differentiation, Cell Death and Disease, Journal of Biological Chemistry, Journal of Experimental Medicine, Journal of Immunology, European Journal of Immunology, Oncogene, Ontotarget, Scientific Reports, Parasite & Vectors, Bioorganic & Medicinal Chemistry, PLoS One, PLoS Neglected Tropical Diseases, International Journal of Antimicrobial Agents, Parasitology International.

Granting Agencies
National Institute of Health (Italy), Multiple sclerosis association (Italy), AIRC (Italy), National Science Foundation (USA), Swiss National Science Foundation (CH).

Teaching and Training Activity

Invited teaching lectures (4-6 hours/year) on apoptosis and cancer at the Faculty of Mathematical, Physical and Natural Sciences of the University of Rome La Sapienza (1992-2012);
Supervisor and Thesis Tutor of 12 undergraduate students of the Faculty of Mathematical, Physical and Natural Sciences of the University of Rome La Sapienza (1992-present);
Supervisor and Thesis Tutor of 6 PhD students in Genetics and Molecular Biology School of Genetics and Molecular Biology, PhD school in Molecular Biology and Medicine of the University of Rome La Sapienza (1995-present);
Tutor of 6 postdoctoral fellowships (FIRC, EC, Fondazioni Buzzati-Traverso), and 5 young researchers (assegni di ricerca)
Training of 4 technicians

Publications in peer reviewed journals

1. Franco A, Barnaba V, Levrero M, **Ruberti G**, Van Dyke A, Bonavita MS, Balsano F. Effect of 28 consecutive days lymphoblastoid interferon (alpha-IFN) administration on hepatitis B virus related chronic liver disease. *J Hepatol.* 1986;3 Suppl 2: S239-43.
2. Barnaba V, Levrero M, Franco A, **Ruberti G**, Musca A, Bonavita MS, Balsano F. Characterization of effector cells in lymphocytotoxicity to autologous hepatocytes in HBsAg-positive and autoimmune chronic active hepatitis (CAH). *Liver* 1986; 6(1): 45-52.
3. Barnaba V, **Ruberti G**, Levrero M, Balsano F. In vitro induction of HBsAg-specific CD8 CD11 human suppressor T cells. *Immunology* 1987; 62(3): 431-8.
4. Barnaba V, Levrero M, **Ruberti G**, van Dyke A, Perrone A, Musca A, Balsano F. In vitro anti-HBs antibody synthesis from anti-hepatitis B vaccine recipients. *Clin Exp Immunol.* 1987; 70(2): 283-8.

5. Franco A, Barnaba V, **Ruberti G**, Benvenuto R, Balsano C, Musca A. Liver-derived T cell clones in autoimmune chronic active hepatitis: accessory cell function of hepatocytes expressing class II major histocompatibility complex molecules. *Clin Immunol Immunopathol.* 1990; 54(3):382-94.
6. Puré E, K Inaba, MT Crowley, L Tardelli, MD Witmer-Pack, **G Ruberti**, CG Fathman and RM Steinman. Antigen processing by epidermal Langerhans cells correlates with the level of biosynthesis of major histocompatibility complex class II molecules and expression of invariant chain. *J. Exp. Med*. 1990; 172: 1459-1469.
7. McClure GC, **G Ruberti**, CG Fathman, HA Herlich and AB Begovich. DRB1*Ly10- a new DRB1 allele and its haplotypic association. *Immunogenetics* 1990; 32: 214-217.
8. **Ruberti G**, AB Begovich, AC Steere, W Klitz, HA Erlich and CG Fathman. Molecular analysis of the role of the HLA class II genes, DRB1, DQA1, DQB1 and DPB1 in susceptibility to Lyme Arthritis. *Human Immunol*. 1991; 31: 20-27.
9. **Ruberti G,** A Gaur, CG Fathman and AM Livingstone. The T cell receptor repertoire influences Vβ element usage in response to myoglobin. *J. Exp. Med.* 1991; 174: 83-92.
10. **Ruberti G,** AM Livingstone, JS Danska, A Gaur, and CG Fathman. Analysis of the ternary complex of antigen, MHC and T cell receptor: the influence of the T cell receptor Vβ repertoire on the Vβ gene element usage. *Res. Immunol.* 1991; 142: 491-493.
11. **Ruberti G,** KS Sellins, CM Hill, RN Germain, CG Fathman and AM Livingstone. Presentation of antigens by mixed isotype class II molecules in normal H-2d mice. *J. Exp. Med.* 1992; 175: 157-162.
12. Gaur A, **Ruberti G**, Haspel R, Mayer JP, Fathman CG. Requirement for CD8+ cells in T cell receptor peptide-induced clonal unresponsiveness. *Science* 1993; 259(5091):91-4.
13. **Ruberti G**, V Paragas, K Dewey and CG Fathman. Selection for amino acid sequence and Jβ element usage in β chain of DBA/2Vβa and DBA/2Vβb derived myoglobin specific T cell clones. *J. Immunol.* 1993; 151: 6185-6194.
14. Fiucci, G., **Ruberti, G**. Detection of polymorphisms within the FAS cDNA gene sequence by GC clampdenaturing gradient gel electrophoresis. *Immunogenetics* 1994; 39 (6): 437-439.
15. Cascino, I., Fiucci, G., Papoff, G., **Ruberti, G**. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing *J of Immunol* 1995; 154 (6): 2706-2713.
16. Cifone, MG, Roncaioli, P, De Maria, R, Camarda, G, Santoni, A, **Ruberti, G,** Testi, R. Multiple pathways originate at the Fas/APO-1 (CD95) receptor: Sequential involvement of phosphatidylcholine specific phospholipase C and acidic sphingomyelinase in the propagation of the apoptotic signal *EMBO Journal* 1995; 14 (23): 5859-5868**.**
17. Cascino, I, Papoff, G, De Maria, R, Testi, R, **Ruberti, G.** Fas/Apo-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis *J. Immunol* 1996; 156 (1): 13-17.
18. Ruberti G, Cascino I, Papoff G, Eramo A. Fas splicing variants and their effect on apoptosis. *Adv Exp Med Biol.* 1996; 406:125-34. Review.
19. Cascino I, Papoff G, Eramo A, Ruberti G. Soluble Fas/Apo-1 splicing variants and apoptosis. *Front Biosci.* 1996; 1:d12-8. Review.
20. Papoff, G, Cascino, I, Eramo, A, Starace, G, Lynch, DH, **Ruberti, G.** An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro. *J of Immunol* 1996; 156 (12): 4622-4630.
21. Baiocchi, RA, Khatri, VP, Lindemann, MJ, Ross, ME, Papoff, G, Caprio, AJ, Caprio, TV, Fenstermaker, R, **Ruberti, G,** Bernstein, ZP, Caligiuri, MA. Phenotypic and functional analysis of Fas (CD95) expression in primary central nervous system lymphoma of patients with acquired immunodeficiency syndrome. *Blood* 1997; 90 (5): 1737-1746.
22. Giordano, C., Stassi, G., De Maria, R., Todaro, M., Richiusa, P., Papoff, G., **Ruberti, G**., Bagnasco, M., Testi, R., Galluzzo, A. Potential involvement of fas and its ligand in the pathogenesis of Hashimoto'sthyroiditis. *Science* 1997; 275 (5302): 960-963.
23. Signore A, Annovazzi A, Procaccini E, Beales PE, Spencer J, Testi R, **Ruberti G**. CD95 and CD95-ligand expression in endocrine pancreas of NOD, NOR and BALB/c mice. *Diabetologia* 1997; 40(12):1476-9.
24. Häusler, P, Papoff, G, Eramo, A, Reif, K., Cantrell, DA, **Ruberti, G**. Protection of CD95-mediated apoptosis by activation of phosphatidylinositide 3-kinase and protein kinase B. *Eur. J. of Immunol* 1998; 28 (1): 57-69.

25. Cascino I, Ballerini C, Audino S, Rombolà G, Massacesi L, Colombo G, Scorza Smeraldi R, d'Alfonso S, Momigliano Richiardi P, Tosi R, **Ruberti G.** Fas gene polymorphisms are not associated with systemic lupus erythematosus, multiple sclerosis and HIV infection. *Dis Markers* 1998, 13(4): 221-5.
26. **Ruberti G**, Signore A. CD95 ligand expression on alpha cells: protection or killing? *Diabetes Metab Rev* 1998; 14(2): 191-2.
27. Prasad, NKA, Papoff, G, Zeuner, A, Bonnin, E, Kazatchkine, MD, **Ruberti, G,** Kaveri, SV. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: A novel mechanism of action of IVIg involving the Fas apoptotic pathway. *J of Immunol* 1998; 161 (7): 3781-3790.
28. Signore A, Annovazzi A, Gradini R, Liddi R, **Ruberti G.** Fas and Fas ligand-mediated apoptosis and its role in autoimmune diabetes. *Diabetes Metab Rev* 1998; 14(3):197-206. Review.
29. Tolomeo M, Dusonchet L, Meli M, Grimaudo S, D'Alessandro N, Papoff G, **Ruberti G**, Rausa L. The CD95/CD95 ligand system is not the major effector in anticancer drug-mediated apoptosis. *Cell Death Differ* 1998; 5(9): 735-42.
30. Papoff, G, Hausler, P, Eramo, A, Pagano, MG, Di Leve, G, Signore, A, **Ruberti, G.** Identification and characterization of a ligand-independent oligomerization domain in the extracellular region of the CD95 death receptor *J. Biol Chem* 1999; 274 (53): 38241-38250.
31. Signore, A, Annovazzi, A, Giacalone, P, Beales, PE, Valorani, MG, Vestri, AR, **Ruberti, G,** Manfrini, S, Pozzilli, P, Bulfone-Paus, S. Reduced cumulative incidence of diabetes but not insulitis following administration of chimeric human IL-15-murine IgG2b in NOD mice *Diabetes/MetabolismResearch and Reviews* 2003; 19 (6): 464-468.
32. Meli, M, Tolomeo, M, D'Alessandro, N, Grimaudo, S, Notarbartolo, M, Papoff, G, **Ruberti, G,** Rausa, L, Dusonchet, L. Resistance to Gemcitabine in a Lymphoma Cell Line Resistant to Fas-mediated Apoptosis *Anticancer Research* 2004; 24 (2 B): 851-857.
33. Varambally, S, Bar-Dayan, Y, Bayry, J, Lacroix-Desmazes, S, Horn, M, Sorel, M, Bar-Dayan, Y, **Ruberti, G,** Kazatchkine, MD, Kaveri, SV. Natural human polyreactive IgM induce apoptosis of lymphoid cell lines and human peripheral blood mononuclear cells *International Immunol* 2004; 16 (3): 517-524.
34. Malquori L, Carsetti L, **Ruberti G.** The 3'-UTR of the human CTLA4 mRNA can regulate mRNA stability and translational efficiency. *Biochim Biophys Acta – Gene Regulatory Mechnisms* 2008; 1779 (1): 60-5.
35. Papoff G, Trivieri N, Crielesi R, Ruberti F, Marsilio S, **Ruberti G.** FADD-calmodulin interaction: a novel player in cell cycle regulation *Biochim Biophys Acta (BBA) – Mol Cell Res* 2010; 1803(8): 898-911.
36. Papoff G, Trivieri N, Marsilio S, Crielesi R, Lalli C, Castellani L, Balog EM, **Ruberti G**. N-Terminal and C-Terminal Domains of Calmodulin Mediate FADD and TRADD Interaction. PLoS One. 2015 Feb 2;10(2):e0116251. doi: 10.1371/journal.pone.0116251. eCollection 2015.
37. Lalli C, Guidi A, Gennari N, Altamura S, Bresciani A, **Ruberti G**. Development and Validation of a Luminescence-based, Medium-Throughput Assay for Drug Screening in Schistosoma mansoni. PLoS Negl Trop Dis. 2015 Jan 30;9(1):e0003484. doi: 10.1371/journal.pntd.0003484. eCollection 2015 Jan.
38. Guidi A, Lalli C, Perlas E, Bolasco G, Nibbio M, Monteagudo E, Bresciani A, **Ruberti G.** Discovery and Characterization of Novel Anti-schistosomal Properties of the Anti-anginal Drug, Perhexiline and Its Impact on Schistosoma mansoni Male and Female Reproductive Systems. PLoS Negl Trop Dis. 2016 Aug 12;10(8):e0004928. doi: 10.1371/journal.pntd.0004928. eCollection 2016 Aug. PMID: 27518281
39. Presutti D, Santini S, Cardinali B, Papoff G, Lalli C, Samperna S, Fustaino V, Giannini G, **Ruberti G.** MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells. PLoS One. 2015 Nov 18;10(11):e0143333. doi: 10.1371/journal.pone.0143333. eCollection 2015. PMID: 26580964
40. Guidi A, Lalli C, Gimmelli R, Nizi E, Andreini M, Gennari N, Saccoccia F, Harper S, Bresciani A, **Ruberti G.** Discovery by organism based high-throughput screening of new multi-stage compounds affecting Schistosoma mansoni viability, egg formation and production. PLoS Negl Trop Dis. 2017 Oct 6;11(10):e0005994. doi: 10.1371/journal.pntd.0005994. eCollection 2017 Oct. PMID: 28985236

41. Compagnone M, Gatti V, Presutti D, **Ruberti G**, Fierro C, Markert EK, Vousden KH, Zhou H, Mauriello A, Anemone L, Bongiorno-Borbone L, Melino G, Peschiaroli A. ΔNp63-mediated regulation of hyaluronic acid metabolism and signaling supports HNSCC tumorigenesis. Proc Natl Acad Sci U S A. 2017 Dec 12;114(50):13254-13259. doi: 10.1073/pnas.1711777114. Epub 2017 Nov 21. PMID: 29162693
42. Fustaino V, Presutti D, Colombo T, Cardinali B, Papoff G, Brandi R, Bertolazzi P, Felici G, **Ruberti G.** Characterization of epithelial-mesenchymal transition intermediate/hybrid phenotypes associated to resistance to EGFR inhibitors in non-small cell lung cancer cell lines. Oncotarget. 2017 Sep 22;8(61):103340-103363. doi: 10.18632/oncotarget.21132. eCollection 2017 Nov 28. PMID: 29262566

Patents

Domanda di brevetto internazionale N. di deposito WO2016/008977 presso EPO in data 16/07/2017 -IRBM Science Park SpA, CNCCS Scarl, CNR “Use of Perhexiline” Inventori: **G. Ruberti,** C. Lalli, A. Guidi (IBCN-CNR), A. Bresciani, N. Gennari, G. Paonessa, E. Nizzi (IRBM Science Park).